PURPOSE: This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2-negative patients from Brazil. METHODS: The study comprised 126 index patients who met NCCN clinical criteria and tested negative for all coding exons and intronic flanking regions of BRCA1/2 genes. Multiplex PCR-based assays were designed to cover the complete coding regions and flanking splicing sites of six genes implicated in HBOC. Sequencing was performed on HiSeq2500 Genome Analyzer. RESULTS: Overall, we identified 488 unique variants. We identified five patients (3.97%) that harbored pathogenic or likely pathogenic variants in four genes: ATM (1), CHEK2 (2), PALB2 (1), and TP53 (1). One hundred and thirty variants were classified as variants of uncertain significance (VUS), 10 of which were predicted to disrupt mRNA splicing (seven non-coding variants and three coding variants), while other six missense VUS were classified as probably damaging by prediction algorithms. CONCLUSION: A detailed mutational profile of non-BRCA genes is still being described in Brazil. In this study, we contributed to filling this gap, by providing important data on the diversity of genetic variants in a Brazilian high-risk patient cohort. ATM, CHEK2, PALB2 and TP53 are well established as HBOC predisposition genes, and the identification of deleterious variants in such actionable genes contributes to clinical management of probands and relatives.
PURPOSE: This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2-negative patients from Brazil. METHODS: The study comprised 126 index patients who met NCCN clinical criteria and tested negative for all coding exons and intronic flanking regions of BRCA1/2 genes. Multiplex PCR-based assays were designed to cover the complete coding regions and flanking splicing sites of six genes implicated in HBOC. Sequencing was performed on HiSeq2500 Genome Analyzer. RESULTS: Overall, we identified 488 unique variants. We identified five patients (3.97%) that harbored pathogenic or likely pathogenic variants in four genes: ATM (1), CHEK2 (2), PALB2 (1), and TP53 (1). One hundred and thirty variants were classified as variants of uncertain significance (VUS), 10 of which were predicted to disrupt mRNA splicing (seven non-coding variants and three coding variants), while other six missense VUS were classified as probably damaging by prediction algorithms. CONCLUSION: A detailed mutational profile of non-BRCA genes is still being described in Brazil. In this study, we contributed to filling this gap, by providing important data on the diversity of genetic variants in a Brazilian high-risk patient cohort. ATM, CHEK2, PALB2 and TP53 are well established as HBOC predisposition genes, and the identification of deleterious variants in such actionable genes contributes to clinical management of probands and relatives.
Entities:
Keywords:
Breast cancer; HBOC; Hereditary cancer; Massive parallel sequencing; Ovarian cancer
Authors: Andrea Desmond; Allison W Kurian; Michele Gabree; Meredith A Mills; Michael J Anderson; Yuya Kobayashi; Nora Horick; Shan Yang; Kristen M Shannon; Nadine Tung; James M Ford; Stephen E Lincoln; Leif W Ellisen Journal: JAMA Oncol Date: 2015-10 Impact factor: 31.777
Authors: A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton Journal: Am J Hum Genet Date: 2003-04-03 Impact factor: 11.025
Authors: Fergus J Couch; Steven N Hart; Priyanka Sharma; Amanda Ewart Toland; Xianshu Wang; Penelope Miron; Janet E Olson; Andrew K Godwin; V Shane Pankratz; Curtis Olswold; Seth Slettedahl; Emily Hallberg; Lucia Guidugli; Jaime I Davila; Matthias W Beckmann; Wolfgang Janni; Brigitte Rack; Arif B Ekici; Dennis J Slamon; Irene Konstantopoulou; Florentia Fostira; Athanassios Vratimos; George Fountzilas; Liisa M Pelttari; William J Tapper; Lorraine Durcan; Simon S Cross; Robert Pilarski; Charles L Shapiro; Jennifer Klemp; Song Yao; Judy Garber; Angela Cox; Hiltrud Brauch; Christine Ambrosone; Heli Nevanlinna; Drakoulis Yannoukakos; Susan L Slager; Celine M Vachon; Diana M Eccles; Peter A Fasching Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Tuya Pal; Doreen Agnese; Mary Daly; Albert La Spada; Jennifer Litton; Myra Wick; Susan Klugman; Edward D Esplin; Gail P Jarvik Journal: Genet Med Date: 2019-12-13 Impact factor: 8.822
Authors: Fergus J Couch; Hermela Shimelis; Chunling Hu; Steven N Hart; Eric C Polley; Jie Na; Emily Hallberg; Raymond Moore; Abigail Thomas; Jenna Lilyquist; Bingjian Feng; Rachel McFarland; Tina Pesaran; Robert Huether; Holly LaDuca; Elizabeth C Chao; David E Goldgar; Jill S Dolinsky Journal: JAMA Oncol Date: 2017-09-01 Impact factor: 31.777
Authors: Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes Journal: N Engl J Med Date: 2015-05-27 Impact factor: 91.245
Authors: Lisa R Susswein; Megan L Marshall; Rachel Nusbaum; Kristen J Vogel Postula; Scott M Weissman; Lauren Yackowski; Erica M Vaccari; Jeffrey Bissonnette; Jessica K Booker; M Laura Cremona; Federica Gibellini; Patricia D Murphy; Daniel E Pineda-Alvarez; Guido D Pollevick; Zhixiong Xu; Gabi Richard; Sherri Bale; Rachel T Klein; Kathleen S Hruska; Wendy K Chung Journal: Genet Med Date: 2015-12-17 Impact factor: 8.822
Authors: Thomas P Slavin; Kara N Maxwell; Jenna Lilyquist; Joseph Vijai; Kenneth Offit; Katherine L Nathanson; Fergus J Couch; Susan L Neuhausen; Steven N Hart; Vignesh Ravichandran; Tinu Thomas; Ann Maria; Danylo Villano; Kasmintan A Schrader; Raymond Moore; Chunling Hu; Bradley Wubbenhorst; Brandon M Wenz; Kurt D'Andrea; Mark E Robson; Paolo Peterlongo; Bernardo Bonanni; James M Ford; Judy E Garber; Susan M Domchek; Csilla Szabo; Jeffrey N Weitzel Journal: NPJ Breast Cancer Date: 2017-06-09